◉ HEADLINES

MACC secures court order to freeze RM2b worth of Palantir shares linked to Tarek Obaid

The High Court has granted the Malaysian Anti-Corruption Commission (MACC) a restraining order on 2.5 million shares in Palantir Technologies Inc., allegedly acquired by 1MDB-linked financier Tarek Obaid using misappropriated funds

6:05 PM MYT

 

KUALA LUMPUR – The Malaysian Anti-Corruption Commission (MACC) has obtained a High Court order to restrain any dealings involving 2.5 million shares of Palantir Technologies Inc., registered under the name of Saudi businessman Tarek Essam Ahmad Obaid.

Judge Datuk Azhar Abdul Hamid granted the order under Section 53 of the Anti-Money Laundering, Anti-Terrorism Financing and Proceeds of Unlawful Activities Act 2001 (AMLATFPUAA) during proceedings at the Kuala Lumpur High Court today.

The application, filed by MACC on September 26, was based on findings that Obaid—better known as Tarek Obaid—had received, transferred and utilised funds misappropriated from 1Malaysia Development Berhad (1MDB) in 2010.

Investigators allege that the funds, channelled into his personal bank account, were later used to acquire Palantir Technologies shares worth USD2 million.

The shares, now estimated to be valued at USD448 million (over RM2 billion), are barred from being sold or traded under the restraining order.

MACC said the action marks a significant step in recovering assets linked to the 1MDB financial scandal. – October 3, 2025

Topics

 

◉ Popular

38% of AirAsia flights delayed in 2024: Loke

Minister outlines measures to improve on-time performance, including incentives, penalties, and full refunds for major delays

Ozil warns Malaysia: Invest in youth or fall behind in global football race

Former Real Madrid and Arsenal star says Malaysia must commit to long-term grassroots and academy development, stressing that sustainable success in world football demands patience, structure, and unwavering belief in youth systems

Promising Malaysian cancer vaccine awaits funding to begin long-delayed human trials

Seven years on, researchers say strong preclinical results persist, but lack of funding continues to hold back critical next-stage testing

◉ Related